CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Theradex Oncology Experts

Theradex is an international contract research organization providing complete professional services for the clinical research and development of pharmaceutical compounds, medical devices and diagnostic tests in the areas of oncology and

Medical Center Compounding

Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Raland Technologies

Raland Technologies is a Fairport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Yamanouchi Pharma Ttechnologies

Yamanouchi Pharma Ttechnologies, Inc. is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.